CloudCath

CloudCath specializes in innovative monitoring solutions, enhancing patient safety and care for those undergoing peritoneal dialysis (PD) through real-time data and insights. CloudCath provides advanced monitoring solutions for patients undergoing peritoneal dialysis. Founded by Aly Badry and Eric Yu, the company is based in San Francisco, US. In December 2019, it raised USD 7.

06 mn in Series A funding led by Integral Capital Partners, with participation from FundRx, Coconut Tree Investments, Stanford-StartX Fund, and The Capital Partnership (U. K. ) Limited. The total amount raised so far is USD 7.

06 mn, with a current company valuation of USD 38. 53 mn. CloudCath specializes in advanced monitoring solutions for patients undergoing peritoneal dialysis (PD). Their flagship product, CloudCath Connect™ PD, integrates optical analysis technology with an Internet of Things (IoT) device to monitor dialysate effluent in real time.

It measures the turbidity of discarded fluid, providing healthcare teams with vital insights and offering early indicators of complications such as peritonitis, allowing caregivers an average notice of 4. 1 days prior to diagnosis. The technology is designed for use in both healthcare facilities and home settings, making it accessible to a wide range of patients and healthcare providers across North America and Europe. CloudCath generates revenue through a subscription-based model for its CloudCath Connect™ PD system.

This model includes ongoing support and access to proprietary monitoring technology, which enhances patient care and communication between patients and healthcare teams. Transactions may involve direct sales to healthcare facilities or partnerships with dialysis providers, tailored to meet the specific needs of patients. Pricing details for subscriptions and services are not disclosed, focusing instead on improving outcomes in peritoneal dialysis management. CloudCath's future growth strategy includes the development of new products aimed at enhancing monitoring capabilities for peritoneal dialysis, with specific launch dates to be confirmed.

The company plans to expand into additional markets, particularly targeting regions in North America and Europe where home dialysis solutions are increasingly in demand. The funding raised in December 2019 will be utilized to support these product developments and market expansion efforts.